Does Florida Medicaid Cover Wegovy or Zepbound? No Published Route as of November 2026

No. Florida’s Medicaid state plan says none of the drugs in the weight-loss class are covered, and its coverage policy lists weight control medications as a non-covered item.^[1][2] As of November 2026, Wegovy and Zepbound are missing from the state’s preferred drug list, and its only GLP-1 criteria are for type 2 diabetes.^[4][5] We found no published path for heart disease, sleep apnea or MASH.

What do Florida's documents say about weight-loss drugs?

Three layers point the same way. States may leave weight-loss agents out of Medicaid under federal law, and Florida’s state plan, in pages CMS approved with a September 30, 2025 effective date, takes that option in plain terms: under “agents when used for anorexia, weight loss, weight gain,” it says “None of the drugs under this drug class are covered.”^[1][14] The state’s Prescribed Drug Services Coverage Policy, which a state rule makes binding on providers, names “weight control medications” among the things it will not pay for.^[2][3] And the drug list and criteria page simply have nothing for the two brands.^[4][6]

One oddity is Saxenda, which next-door Georgia Medicaid covers only for teens with high cholesterol. The Summary of Drug Limitations carries a line setting its minimum age at 12.^[7] That summary describes limits and says its drugs may or may not need prior authorization, and it does not promise payment. Saxenda does not appear on the preferred drug list, so the line should not be read as coverage.^[4][7]

Is there a route for heart disease, sleep apnea or MASH?

Not one the state has published. Wegovy’s label includes reducing major heart events and treating the liver disease MASH, and Zepbound’s includes moderate to severe sleep apnea.^[15][16] Other large states have written criteria for those uses; Texas Medicaid’s criteria are one example. Florida’s criteria page, as read on November 1, 2026, has a GLP-1 page limited to type 2 diabetes and nothing for either brand.^[5][6]

That silence leaves a real question. The state plan wording covers agents “when used for” weight loss, and the federal exclusion is written around that purpose, so a heart or sleep apnea prescription is arguably a different case.^[1][14] We found no Florida document that says how such a request is handled, so we cannot tell you it will be approved or that it will always be refused. If this is your situation, have your prescriber ask your plan in writing, and appeal a denial on the ground that the use is not weight loss. Our explainer on how a sleep apnea approval changes the Medicaid question lays out that argument, and the sleep apnea evidence supports the clinical part of the file.

Does Florida Medicaid cover Ozempic or Mounjaro for diabetes?

Yes, with a clinical prior authorization that is stricter than many people expect. Mounjaro, Ozempic injection and tablets, Rybelsus and Trulicity are preferred. Generic liraglutide, exenatide and Victoza are non-preferred and need a prior try of a preferred drug.^[5] Each request needs:

• A type 2 diabetes diagnosis, with age limits of 18 for Ozempic and Rybelsus and 10 for Mounjaro, Trulicity and Victoza.^[5]
• An HbA1c of at least 6.5% from the last six months, with documents.^[5]
• Trial and failure of metformin within the last two years, unless it is contraindicated or not tolerated.^[5]
• For renewal, evidence of clinical response, such as a falling HbA1c, and no treatment-limiting side effects. Approvals last up to one year.^[5]

Because the test is a diabetes diagnosis, prediabetes or obesity alone fails it. Asking a prescriber to record diabetes you do not have is fraud and puts your benefit at risk, as the federal false-statement rule makes clear.

Do Statewide Medicaid Managed Care plans follow the same list?

Enrolling in a Statewide Medicaid Managed Care plan does not get around the state plan’s exclusion. Florida law requires each plan to post its formulary or preferred drug list online in searchable form, which gives you a place to check the current listing.^[10] Sunshine Health, for one, says it follows AHCA’s preferred drug list guidelines.^[11] We did not read every plan’s list, so check yours by brand name and ask the plan in writing if the two appear to differ.

What about children and rare obesity conditions?

Federal child-health rules reach further than the adult benefit. AHCA’s own overview says services for people under 21 that go beyond Florida’s stated coverage may be approved if medically necessary.^[9] Wegovy’s label includes obesity from age 12, so a family that gets a flat refusal can ask for a medical necessity review under EPSDT by name.^[15] The overview does not mention GLP-1s, so approval is not assured.

One drug for obesity does have criteria: Imcivree (setmelanotide), for genetically confirmed POMC, PCSK1 or LEPR deficiency, Bardet-Biedl syndrome and acquired hypothalamic obesity, from age 2.^[8] These are rare conditions, and Imcivree is not a GLP-1.

How do you appeal a denial in Florida?

• Plan members. Appeal to the plan within 60 calendar days of the notice.^[13] If the plan does not resolve it wholly in your favor, AHCA must receive your fair hearing request within 120 days of the date the plan’s resolution notice was sent.^[12]
• Fee-for-service. AHCA must receive a hearing request within 90 days of the date the required notice was sent.^[12]
• Timing. The rule calls for a final order within 90 days of the request, unless the time is extended.^[12]

Appeals have little to hold onto when the diagnosis on the request is obesity alone. They have more when the dispute is about diabetes paperwork or a non-weight use. Our guide to prior authorization and appeals covers what to include.

What are the options if Medicaid won't pay?

Florida’s drug list shows no phentermine or orlistat rows, and the weight control exclusion is not limited to injectables, so older pills are unlikely to be a Medicaid route here.^[2][4] Our phentermine and GLP-1 comparison shows how much less weight those drugs take off if you pay for them yourself.

For the brands, Lilly’s savings card for insured patients excludes Medicaid enrollees.^[17] Self-pay prices in the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and $299 at the starting dose, $399 at 5 mg and $449 at 7.5 mg and up for Lilly’s Zepbound KwikPen or vial, when each refill comes within 45 days.^[17][18] Read each offer’s terms for government-program limits. We compare the routes in the cheapest ways to buy a GLP-1 without insurance.